©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Mar 26, 2015; 7(2): 235-242
Published online Mar 26, 2015. doi: 10.4252/wjsc.v7.i2.235
Published online Mar 26, 2015. doi: 10.4252/wjsc.v7.i2.235
SIRT1 and stem cells: In the forefront with cardiovascular disease, neurodegeneration and cancer
Kenneth Maiese, Cellular and Molecular Signaling, Newark, NJ 07101, United States
Author contributions: Maiese K conceived, designed, and wrote this article.
Supported by The following grants to Kenneth Maiese: American Diabetes Association; American Heart Association; NIH NIEHS; NIH NIA; NIH NINDS; and NIH ARRA.
Conflict-of-interest: The author declares no conflicts of interest.
Correspondence to: Kenneth Maiese, MD, Cellular and Molecular Signaling, 125 Main Street, Newark, NJ 07101, United States. wntin75@yahoo.com
Received: November 2, 2014
Peer-review started: November 2, 2014
First decision: November 27, 2014
Revised: December 31, 2014
Accepted: January 15, 2015
Article in press: January 15, 2015
Published online: March 26, 2015
Processing time: 138 Days and 9.4 Hours
Peer-review started: November 2, 2014
First decision: November 27, 2014
Revised: December 31, 2014
Accepted: January 15, 2015
Article in press: January 15, 2015
Published online: March 26, 2015
Processing time: 138 Days and 9.4 Hours
Core Tip
Core tip: SIRT1, a mammalian homologue of the yeast silent information regulator-2, holds exciting prospects for new therapeutic strategies that can offer reparative processes for cardiac, vascular, and nervous system degenerative disorders as well as targeted control of unchecked cell growth during cancer.